Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...
Travere Therapeutics reported durable biomarker data for FILSPARI in IgA nephropathy, but shares fell 4.5% as markets focus ...
Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease ...
Zacks.com on MSN
CBOE Global (CBOE) Earnings Expected to Grow: Should You Buy?
CBOE Global (CBOE) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...
Zacks Investment Research on MSN
AstraZeneca gets accelerated FDA nod for Ultomiris in IgA nephropathy
AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing ...
MedPage Today on MSN
Trio of IgA nephropathy drugs proves mettle in interim analyses
Significant proteinuria reductions reported, but still awaiting eGFR data ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
阿斯特捷利康 (AZN) 盤中上漲3.04%，所屬行業 醫藥與醫學研究 上漲1.42%，公司漲幅跑贏行業漲幅，行業成交額前三股票 Moderna Inc (MRNA) 下跌 24.58%； Eli Lilly and Co (LLY) 上漲 3.16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results